Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying tissue samples in predicting how well chemotherapy and radiation therapy will kill cancer cells in patients with squamous cell carcinoma of the esophagus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Toyama
• Treatments: Cisplatin; Fluorouracil

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed squamous cell carcinoma of the thoracic esophagus

• Stage IIA, IIB, or III (except T4) disease

• Tumor diameter < 8 cm

• No tumor extension to the cervical esophagus or cardia of the stomach

• No multiple and different histological types of cancer

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• WBC ≥ 4,000/mm³

• Absolute neutrophil count ≥ 2,000/mm³

• Platelet count ≥ 100,000/mm³

• Hemoglobin ≥ 10 g/dL

• AST and ALT ≤ 100 IU/L

• Total serum bilirubin ≤ 1.5 mg/dL

• Creatinine ≤ 1.2 mg/dL

• Creatinine clearance ≥ 60mL/min

• SpO_2 (room air) ≥ 95%

• Not pregnant or nursing

• No abnormal ECG findings requiring treatment

• No interstitial pneumonitis or no pulmonary fibrosis

• No severe complication (e.g., heart failure, renal failure, hepatic failure, or uncontrollable diabetes mellitus)

• No collagen disease (e.g., PSS or dermatomyositis)

• No mental disease

• No active bacterial infection

• No virus infection (i.e., HBV, HCV, PTHA, or HIV)

PRIOR CONCURRENT THERAPY:

• No prior surgery for esophageal cancer

• No prior chemotherapy

• No prior chest radiotherapy